We are live on ! Find out more
MREO

Mereo BioPharma
MREO

86 hedge funds and large institutions have $268M invested in Mereo BioPharma in 2025 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $8.29M | Put options by funds: $3.35M

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

48.13% more ownership

Funds ownership: 13.97% → 62.11% (+48%)

7% more capital invested

Capital invested by funds: $250M → $268M (+$17.5M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 90 → 86 (-4)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

Holders
86
Holders Change
-4
Holders Change %
-4.44%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
12
Increased
31
Reduced
19
Closed
16
Calls
$8.29M
Puts
$3.35M
Net Calls
+$4.95M
Net Calls Change
+$3.19M

Top Buyers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
+$3.91M
2
Goldman Sachs
Goldman Sachs
New York
+$2.33M
3
Aberdeen Group
Aberdeen Group
United Kingdom
+$2.03M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.74M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.01M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$12.2M
2
RSCM
Rock Springs Capital Management
Maryland
-$5.36M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.83M
4
UBS AM
UBS AM
Illinois
-$3.53M
5
Morgan Stanley
Morgan Stanley
New York
-$3.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
SIA
76
Sit Investment Associates
Minnesota
$3K – – –
BIG
77
Brooklyn Investment Group
New York
$2.3K +$2.05K +849 New
EWA
78
EverSource Wealth Advisors
Alabama
$1.27K +$1.13K +470 New
MCM
79
MAI Capital Management
Ohio
$838 – – –
NECFA
80
New England Capital Financial Advisors
Connecticut
$813 – – –
Wells Fargo
81
Wells Fargo
California
$622 -$2.41K -1,000 -81%
S
82
SignatureFD
Georgia
$507 +$451 +187 New
T
83
Transce3nd
Texas
$344 – – –
PS
84
Principal Securities
Iowa
$203 +$104 +43 +134%
US Bancorp
85
US Bancorp
Minnesota
$35 – – –
BNP Paribas Financial Markets
86
BNP Paribas Financial Markets
France
$8 – – –
Adage Capital Partners
87
Adage Capital Partners
Massachusetts
– -$3.83M -1,700,756 Closed
UBS AM
88
UBS AM
Illinois
– -$3.53M -1,569,100 Closed
GPP
89
Great Point Partners
Connecticut
– -$2.87M -1,275,000 Closed
WP
90
Woodline Partners
California
– -$2.13M -947,986 Closed
PA
91
Perceptive Advisors
New York
– -$1.97M -876,961 Closed
IHAM
92
Integral Health Asset Management
New York
– -$1.8M -800,000 Closed
ACP
93
Acuta Capital Partners
California
– -$1.78M -791,815 Closed
DP
94
Diadema Partners
New Jersey
– -$1.19M -492,215 Closed
PAP
95
Persistent Asset Partners
Hong Kong
– -$273K -113,247 Closed
BC
96
BIT Capital
Germany
– -$227K -101,070 Closed
Ameriprise
97
Ameriprise
Minnesota
– -$87.8K -39,030 Closed
HF
98
HRT Financial
New York
– -$35K -15,713 Closed
HSBC Holdings
99
HSBC Holdings
United Kingdom
– -$29.8K -13,577 Closed
ACM
100
ADAR1 Capital Management
Texas
– -$22.5K -10,000 Closed
1 2 3
4
5

MREO Hedge Fund Activity: Q2 2025 in Review

86 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2025, worth a combined $268M — up 7% from $250M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of MREO and 12 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 31 added.

The largest buyer was Frazier Life Sciences Management, adding an estimated $3.91M. The largest seller was Janus Henderson Group, cutting an estimated $12.2M.

  • 86 institutional investors held Mereo BioPharma (MREO) as of Q2 2025, down from 90 in Q1 2025.
  • Funds reported $268M of Mereo BioPharma stock for Q2 2025, up 7% quarter-over-quarter.
  • 12 funds opened new Mereo BioPharma positions in Q2 2025 and 16 closed out, a net change of -4 holders.
  • The largest Mereo BioPharma buyer in Q2 2025 was Frazier Life Sciences Management, an estimated $3.91M added.
  • The largest Mereo BioPharma seller in Q2 2025 was Janus Henderson Group, an estimated $12.2M sold.

Based on aggregated 13F filings for Q2 2025.